ThromboGenics Struggles to Find Patients for Phase II Eye Disease Trial Post author:Sam Post published:December 7, 2017 Post category:BioPharma Resources redirected to progress new drug candidates to clinic in H1 2018. Source: BioSpace You Might Also Like FDA Gives AstraZeneca’s Imfinzi the Nod for New Lung Cancer Indication February 19, 2018 Sarepta Auctions Off Its Priority Review Voucher for Exondys 51 to Gilead for $125 Million February 20, 2017 <b>Victoria Laughman</b> Named Executive Vice President Of Sales For Opko Health's BioReference August 17, 2017
Sarepta Auctions Off Its Priority Review Voucher for Exondys 51 to Gilead for $125 Million February 20, 2017
<b>Victoria Laughman</b> Named Executive Vice President Of Sales For Opko Health's BioReference August 17, 2017
